{"id":331602,"date":"2026-10-29T11:59:13","date_gmt":"2026-10-29T06:29:13","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=331602"},"modified":"2026-10-29T11:59:13","modified_gmt":"2026-10-29T06:29:13","slug":"midcap-debt-to-equity-above-1-stocks-to-watch-multibagger-potential","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/midcap-debt-to-equity-above-1-stocks-to-watch-multibagger-potential\/","title":{"rendered":"4 Midcap Debt to Equity Above 1 Stocks to Watch for Future Multibagger Potential: Ashok Leyland, Sundaram Finance, Narayana Health and Nuvama"},"content":{"rendered":"<p style=\"border-left:4px solid #1F4E79;background:#EBF3FB;padding:10px 16px;font-style:italic;\"><em>Ashok Leyland Rs 144.85. Sundaram Finance Rs 3,924.20. Narayana Health Rs 1,723.10. Nuvama Rs 1,744.70. Market caps from Rs 32,827 crore to Rs 86,231 crore. Data as of 28 Oct 2026.<\/em><\/p>\n<div style=\"background:#F0F9FF;border-left:4px solid #2E7D32;border-radius:6px;padding:14px 18px;margin:18px 0;\">\n<p style=\"margin:0;color:#1F4E79;font-size:14px;\"><strong>Quick Answer<\/strong><\/p>\n<p style=\"margin:8px 0 0;\">Ashok Leyland, Sundaram Finance, Narayana Health and Nuvama are the 4 picks in this debt to equity above 1 stocks watchlist, with market caps between Rs 32,827 crore and Rs 86,231 crore. Ashok Leyland stands out for the largest market cap at Rs 86,231 crore, while Sundaram Finance offers the strongest latest-quarter profit growth at 38.14%. PE ratios run from 20.17 to 42.69, so compare each one with its industry PE before investing. All figures are as of 28 October 2026.<\/p>\n<\/p><\/div>\n<p>Debt to equity above 1 stocks to watch for multibagger potential start with a simple filter: size, a clean financial record and earnings that keep growing. Ashok Leyland, Sundaram Finance, Narayana Health and Nuvama meet that test, with market caps from Rs 32,827 crore to Rs 86,231 crore and Ashok Leyland offering the largest market cap at Rs 86,231 crore. Each of these companies has a market capitalisation between Rs 30,000 crore and Rs 1,00,000 crore and a debt to equity ratio above 1, a return on equity of at least 10 per cent and profit growth in FY26 and in the latest quarter, and net profit rose in FY26 and in the latest quarter.<\/p>\n<p>This list covers companies with a market capitalisation between Rs 30,000 crore and Rs 1,00,000 crore and a debt to equity ratio above 1, a return on equity of at least 10 per cent and profit growth in FY26 and in the latest quarter, rising profit in FY26 and the latest quarter, and complete, verifiable financials, ranked by market capitalisation. Each company has a market cap between Rs 30,000 crore and Rs 1 lakh crore. Investors screening debt to equity above 1 stocks usually begin with size and balance sheet strength, and this list follows the same logic. All figures are as of 28 October 2026 and are drawn from NSE and BSE data and company filings.<\/p>\n<p style=\"margin-top:24px;\"><a href=\"https:\/\/univest.in\/user\/log-in?utm_source=blogs&#038;utm_medium=debt-to-equity-above-stocks\"><strong>Click Here &#8211; Get Free Investment Predictions<\/strong><\/a><\/p>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/midcap-debt-to-equity-above-1-stocks-to-watch-multibagger-potential\/#What_Are_Debt_to_Equity_Above_1_Stocks_and_Why_Do_They_Attract_Multibagger_Interest\" title=\"What Are Debt to Equity Above 1 Stocks and Why Do They Attract Multibagger Interest?\">What Are Debt to Equity Above 1 Stocks and Why Do They Attract Multibagger Interest?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/midcap-debt-to-equity-above-1-stocks-to-watch-multibagger-potential\/#Debt_to_Equity_Above_1_Stocks_at_a_Glance_Price_Market_Cap_PE_ROE_and_Price_to_Book\" title=\"Debt to Equity Above 1 Stocks at a Glance: Price, Market Cap, PE, ROE and Price to Book\">Debt to Equity Above 1 Stocks at a Glance: Price, Market Cap, PE, ROE and Price to Book<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/midcap-debt-to-equity-above-1-stocks-to-watch-multibagger-potential\/#Ashok_Leyland_Return_on_Equity_of_2437\" title=\"Ashok Leyland: Return on Equity of 24.37%\">Ashok Leyland: Return on Equity of 24.37%<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/midcap-debt-to-equity-above-1-stocks-to-watch-multibagger-potential\/#Sundaram_Finance_Quarterly_Profit_Up_3814\" title=\"Sundaram Finance: Quarterly Profit Up 38.14%\">Sundaram Finance: Quarterly Profit Up 38.14%<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/midcap-debt-to-equity-above-1-stocks-to-watch-multibagger-potential\/#Narayana_Health_2406_Profit_CAGR_Since_FY22\" title=\"Narayana Health: 24.06% Profit CAGR Since FY22\">Narayana Health: 24.06% Profit CAGR Since FY22<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/midcap-debt-to-equity-above-1-stocks-to-watch-multibagger-potential\/#Nuvama_Return_on_Equity_of_2526\" title=\"Nuvama: Return on Equity of 25.26%\">Nuvama: Return on Equity of 25.26%<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/midcap-debt-to-equity-above-1-stocks-to-watch-multibagger-potential\/#Debt_to_Equity_Above_1_Stocks_Financial_Comparison_on_Growth_and_Margins\" title=\"Debt to Equity Above 1 Stocks: Financial Comparison on Growth and Margins\">Debt to Equity Above 1 Stocks: Financial Comparison on Growth and Margins<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/midcap-debt-to-equity-above-1-stocks-to-watch-multibagger-potential\/#Institutional_Holding_in_Ashok_Leyland_Sundaram_Finance_Narayana_Health_and_Nuvama\" title=\"Institutional Holding in Ashok Leyland, Sundaram Finance, Narayana Health and Nuvama\">Institutional Holding in Ashok Leyland, Sundaram Finance, Narayana Health and Nuvama<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/midcap-debt-to-equity-above-1-stocks-to-watch-multibagger-potential\/#Risks_to_Weigh_in_Debt_to_Equity_Above_1_Stocks\" title=\"Risks to Weigh in Debt to Equity Above 1 Stocks\">Risks to Weigh in Debt to Equity Above 1 Stocks<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/midcap-debt-to-equity-above-1-stocks-to-watch-multibagger-potential\/#How_to_Choose_Between_Debt_to_Equity_Above_1_Stocks\" title=\"How to Choose Between Debt to Equity Above 1 Stocks\">How to Choose Between Debt to Equity Above 1 Stocks<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/midcap-debt-to-equity-above-1-stocks-to-watch-multibagger-potential\/#Conclusion\" title=\"Conclusion\">Conclusion<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/midcap-debt-to-equity-above-1-stocks-to-watch-multibagger-potential\/#Frequently_Asked_Questions_on_Debt_to_Equity_Above_1_Stocks_to_Watch\" title=\"Frequently Asked Questions on Debt to Equity Above 1 Stocks to Watch\">Frequently Asked Questions on Debt to Equity Above 1 Stocks to Watch<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/midcap-debt-to-equity-above-1-stocks-to-watch-multibagger-potential\/#Which_are_the_best_debt_to_equity_above_1_stocks_to_watch_for_multibagger_potential\" title=\"Which are the best debt to equity above 1 stocks to watch for multibagger potential?\">Which are the best debt to equity above 1 stocks to watch for multibagger potential?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/univest.in\/blogs-2\/midcap-debt-to-equity-above-1-stocks-to-watch-multibagger-potential\/#Is_Nuvama_a_good_stock_for_long-term_investors\" title=\"Is Nuvama a good stock for long-term investors?\">Is Nuvama a good stock for long-term investors?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/univest.in\/blogs-2\/midcap-debt-to-equity-above-1-stocks-to-watch-multibagger-potential\/#Can_Narayana_Health_become_a_multibagger_from_here\" title=\"Can Narayana Health become a multibagger from here?\">Can Narayana Health become a multibagger from here?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/univest.in\/blogs-2\/midcap-debt-to-equity-above-1-stocks-to-watch-multibagger-potential\/#What_is_the_market_cap_of_Ashok_Leyland_Sundaram_Finance_Narayana_Health_and_Nuvama\" title=\"What is the market cap of Ashok Leyland, Sundaram Finance, Narayana Health and Nuvama?\">What is the market cap of Ashok Leyland, Sundaram Finance, Narayana Health and Nuvama?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/univest.in\/blogs-2\/midcap-debt-to-equity-above-1-stocks-to-watch-multibagger-potential\/#What_are_the_risks_of_investing_in_debt_to_equity_above_1_stocks\" title=\"What are the risks of investing in debt to equity above 1 stocks?\">What are the risks of investing in debt to equity above 1 stocks?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-18\" href=\"https:\/\/univest.in\/blogs-2\/midcap-debt-to-equity-above-1-stocks-to-watch-multibagger-potential\/#Is_Sundaram_Finance_trading_below_its_industry_PE\" title=\"Is Sundaram Finance trading below its industry PE?\">Is Sundaram Finance trading below its industry PE?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-19\" href=\"https:\/\/univest.in\/blogs-2\/midcap-debt-to-equity-above-1-stocks-to-watch-multibagger-potential\/#How_much_do_institutions_hold_in_Ashok_Leyland_Sundaram_Finance_Narayana_Health_and_Nuvama\" title=\"How much do institutions hold in Ashok Leyland, Sundaram Finance, Narayana Health and Nuvama?\">How much do institutions hold in Ashok Leyland, Sundaram Finance, Narayana Health and Nuvama?<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"What_Are_Debt_to_Equity_Above_1_Stocks_and_Why_Do_They_Attract_Multibagger_Interest\"><\/span><strong>What Are Debt to Equity Above 1 Stocks and Why Do They Attract Multibagger Interest?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Debt to equity above 1 stocks are shares of mid sized companies that use more debt than shareholder money to fund growth, a model common in infrastructure, finance and capital heavy businesses. The four here cover commercial vehicles, vehicle finance, hospitals and wealth management.<\/p>\n<p>Debt funded growth can raise returns for shareholders when the borrowing earns more than it costs, and rising profit shows that is happening. Investors should still watch interest cover. Within debt to equity above 1 stocks, the four companies show rising profit. For debt to equity above 1 stocks, both FY26 and the latest quarter showed growth. Whichever way you read debt to equity above 1 stocks, the common thread is rising profit backed by complete financial data. A sensible way to study debt to equity above 1 stocks is to look at profit growth, returns and valuation side by side. Below, each of debt to equity above 1 stocks gets its own breakdown of growth, returns and valuation. Treat debt to equity above 1 stocks as a research list, since share prices and rankings change with every earnings season.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Debt_to_Equity_Above_1_Stocks_at_a_Glance_Price_Market_Cap_PE_ROE_and_Price_to_Book\"><\/span><strong>Debt to Equity Above 1 Stocks at a Glance: Price, Market Cap, PE, ROE and Price to Book<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Prices are closing prices as of 28 October 2026. Sundaram Finance has the lowest PE of the group at 20.17, while Nuvama posts the highest return on equity at 25.26%.<\/p>\n<table style=\"border-collapse:collapse;width:100%;margin:16px 0;\">\n<thead>\n<tr>\n<th style=\"border:1px solid #BBBBBB;background:#1F4E79;color:#FFFFFF;padding:8px;text-align:left;\">Stock<\/th>\n<th style=\"border:1px solid #BBBBBB;background:#1F4E79;color:#FFFFFF;padding:8px;text-align:left;\">CMP (Rs)<\/th>\n<th style=\"border:1px solid #BBBBBB;background:#1F4E79;color:#FFFFFF;padding:8px;text-align:left;\">Market Cap (Rs Cr)<\/th>\n<th style=\"border:1px solid #BBBBBB;background:#1F4E79;color:#FFFFFF;padding:8px;text-align:left;\">PE<\/th>\n<th style=\"border:1px solid #BBBBBB;background:#1F4E79;color:#FFFFFF;padding:8px;text-align:left;\">Industry PE<\/th>\n<th style=\"border:1px solid #BBBBBB;background:#1F4E79;color:#FFFFFF;padding:8px;text-align:left;\">ROE<\/th>\n<th style=\"border:1px solid #BBBBBB;background:#1F4E79;color:#FFFFFF;padding:8px;text-align:left;\">Price to Book<\/th>\n<th style=\"border:1px solid #BBBBBB;background:#1F4E79;color:#FFFFFF;padding:8px;text-align:left;\">52-Week Range (Rs)<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\"><a href=\"https:\/\/univest.in\/stocks\/ashokley\/ashok-leyland-ltd-share-price-today\">Ashok Leyland<\/a><\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">144.85<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">86,231<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">23.12<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">23.62<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">24.37%<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">6.05<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">134.21 to 215.42<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\"><a href=\"https:\/\/univest.in\/stocks\/sundarmfin\/sundaram-finance-ltd-share-price-today\">Sundaram Finance<\/a><\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">3,924.20<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">44,764<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">20.17<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">17.70<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">13.82%<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">3.01<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">3,902.00 to 5,642.00<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\"><a href=\"https:\/\/univest.in\/stocks\/nh\/narayana-hrudayalaya-ltd-share-price-today\">Narayana Hrudayalaya<\/a><\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">1,723.10<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">34,864<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">42.69<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">60.75<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">17.76%<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">7.68<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">1,589.00 to 2,093.30<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\"><a href=\"https:\/\/univest.in\/stocks\/nuvama\/nuvama-wealth-management-ltd-share-price-today\">Nuvama Wealth Management<\/a><\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">1,744.70<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">32,827<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">30.34<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">33.31<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">25.26%<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">8.00<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">1,096.90 to 2,066.00<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2><span class=\"ez-toc-section\" id=\"Ashok_Leyland_Return_on_Equity_of_2437\"><\/span><strong>Ashok Leyland: Return on Equity of 24.37%<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Ashok Leyland makes trucks, buses and defence vehicles and is among the largest commercial vehicle makers in India. It reported FY26 revenue of Rs 56,946.90 crore, up 16.47% year on year, and net profit of Rs 3,720.98 crore, up 10.00%. Revenue has compounded at 21.28% a year since FY22. Operating margin was 19.17% in FY26.<\/p>\n<p>In the June 2026 quarter, revenue rose 12.29% to Rs 13,258.24 crore and net profit grew 1.53% to Rs 667.77 crore. The share price has gained 106.37% over five years. Domestic institutions raised their holding from 13.61% in July 2025 to 15.76% in June 2026. The stock trades at a PE of 23.12 against an industry PE of 23.62, below the sector average, with a return on equity of 24.37%. The dividend yield is 2.38%.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Sundaram_Finance_Quarterly_Profit_Up_3814\"><\/span><strong>Sundaram Finance: Quarterly Profit Up 38.14%<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Sundaram Finance is one of India&#8217;s oldest non-banking finance companies, with a strong record in commercial vehicle and car loans. It reported FY26 revenue of Rs 9,873.12 crore, up 15.30% year on year, and net profit of Rs 2,005.40 crore, up 10.62%. Net profit has compounded at 17.10% a year since FY22, while revenue has grown 17.69% a year. Operating margin was 77.70% in FY26.<\/p>\n<p>The stock trades at a PE of 20.17 against an industry PE of 17.70, with a return on equity of 13.82%. In the June 2026 quarter, revenue rose 12.76% to Rs 2,653.34 crore and net profit grew 38.14% to Rs 568.86 crore. The share price has gained 68.83% over five years. Domestic institutions raised their holding from 7.22% in June 2025 to 8.00% in June 2026.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Narayana_Health_2406_Profit_CAGR_Since_FY22\"><\/span><strong>Narayana Health: 24.06% Profit CAGR Since FY22<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Narayana Health runs a network of multi-speciality hospitals, with a strong cardiac care franchise and a presence in India and the Cayman Islands. It reported FY26 revenue of Rs 7,996.25 crore, up 43.43% year on year, and net profit of Rs 810.46 crore, up 2.61%. Net profit has compounded at 24.06% a year since FY22, while revenue has grown 20.95% a year. Operating margin was 21.25% in FY26.<\/p>\n<p>In the June 2026 quarter, revenue rose 77.60% to Rs 2,719.11 crore and net profit grew 5.37% to Rs 207.27 crore. The share price has gained 225.59% over five years. Domestic institutions raised their holding from 7.76% in September 2025 to 10.68% in September 2026. The stock trades at a PE of 42.69 against an industry PE of 60.75, below the sector average, with a return on equity of 17.76%.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Nuvama_Return_on_Equity_of_2526\"><\/span><strong>Nuvama: Return on Equity of 25.26%<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Nuvama Wealth Management offers wealth management, asset services and capital markets services to affluent clients and institutions. It reported FY26 revenue of Rs 4,649.65 crore, up 11.52% year on year, and net profit of Rs 1,040.26 crore, up 5.60%. Revenue has compounded at 27.07% a year since FY22. Operating margin was 53.05% in FY26.<\/p>\n<p>The stock trades at a PE of 30.34 against an industry PE of 33.31, below the sector average, with a return on equity of 25.26%. The dividend yield is 1.54%. In the June 2026 quarter, revenue rose 22.88% to Rs 1,381.96 crore and net profit grew 15.83% to Rs 305.64 crore. The share price is up 19.71% over the past year. Domestic institutions raised their holding from 6.37% in June 2025 to 8.49% in June 2026.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Debt_to_Equity_Above_1_Stocks_Financial_Comparison_on_Growth_and_Margins\"><\/span><strong>Debt to Equity Above 1 Stocks: Financial Comparison on Growth and Margins<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The table compares scale and growth across these debt to equity above 1 stocks. Latest quarter means the most recent reported quarter for each company, and only metrics that are positive for every company are shown.<\/p>\n<table style=\"border-collapse:collapse;width:100%;margin:16px 0;\">\n<thead>\n<tr>\n<th style=\"border:1px solid #BBBBBB;background:#1F4E79;color:#FFFFFF;padding:8px;text-align:left;\">Stock<\/th>\n<th style=\"border:1px solid #BBBBBB;background:#1F4E79;color:#FFFFFF;padding:8px;text-align:left;\">Revenue (Rs Cr)<\/th>\n<th style=\"border:1px solid #BBBBBB;background:#1F4E79;color:#FFFFFF;padding:8px;text-align:left;\">Net Profit (Rs Cr)<\/th>\n<th style=\"border:1px solid #BBBBBB;background:#1F4E79;color:#FFFFFF;padding:8px;text-align:left;\">Revenue Growth (YoY)<\/th>\n<th style=\"border:1px solid #BBBBBB;background:#1F4E79;color:#FFFFFF;padding:8px;text-align:left;\">4-Year Revenue CAGR<\/th>\n<th style=\"border:1px solid #BBBBBB;background:#1F4E79;color:#FFFFFF;padding:8px;text-align:left;\">Latest Quarter Revenue Growth<\/th>\n<th style=\"border:1px solid #BBBBBB;background:#1F4E79;color:#FFFFFF;padding:8px;text-align:left;\">Operating Margin (Latest Quarter)<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">Ashok Leyland<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">56,946.90<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">3,720.98<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">16.47%<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">21.28%<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">12.29%<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">20.01%<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">Sundaram Finance<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">9,873.12<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">2,005.40<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">15.30%<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">17.69%<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">12.76%<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">78.41%<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">Narayana Health<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">7,996.25<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">810.46<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">43.43%<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">20.95%<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">77.60%<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">18.75%<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">Nuvama<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">4,649.65<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">1,040.26<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">11.52%<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">27.07%<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">22.88%<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">53.22%<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p style=\"margin-top:24px;\"><a href=\"https:\/\/univest.in\/screeners\"><strong>Check the Univest Screener for live data on these debt to equity above 1 stocks<\/strong><\/a><\/p>\n<h2><span class=\"ez-toc-section\" id=\"Institutional_Holding_in_Ashok_Leyland_Sundaram_Finance_Narayana_Health_and_Nuvama\"><\/span><strong>Institutional Holding in Ashok Leyland, Sundaram Finance, Narayana Health and Nuvama<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Institutional holding shows who is backing these debt to equity above 1 stocks alongside the promoter. The table uses the latest reported quarter for each. Ashok Leyland has the deepest institutional backing, with FII and DII together holding 36.44% as of June 2026. Domestic institutions increased their holding over the past year in Ashok Leyland (from 13.61% to 15.76%), Sundaram Finance (from 7.22% to 8.00%), Narayana Health (from 7.76% to 10.68%) and Nuvama (from 6.37% to 8.49%).<\/p>\n<table style=\"border-collapse:collapse;width:100%;margin:16px 0;\">\n<thead>\n<tr>\n<th style=\"border:1px solid #BBBBBB;background:#1F4E79;color:#FFFFFF;padding:8px;text-align:left;\">Stock<\/th>\n<th style=\"border:1px solid #BBBBBB;background:#1F4E79;color:#FFFFFF;padding:8px;text-align:left;\">Promoter<\/th>\n<th style=\"border:1px solid #BBBBBB;background:#1F4E79;color:#FFFFFF;padding:8px;text-align:left;\">FII<\/th>\n<th style=\"border:1px solid #BBBBBB;background:#1F4E79;color:#FFFFFF;padding:8px;text-align:left;\">DII<\/th>\n<th style=\"border:1px solid #BBBBBB;background:#1F4E79;color:#FFFFFF;padding:8px;text-align:left;\">Public<\/th>\n<th style=\"border:1px solid #BBBBBB;background:#1F4E79;color:#FFFFFF;padding:8px;text-align:left;\">Quarter<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">Ashok Leyland<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">51.51%<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">20.68%<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">15.76%<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">12.05%<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">June 2026<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">Sundaram Finance<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">37.21%<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">18.58%<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">8.00%<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">36.21%<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">June 2026<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">Narayana Health<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">63.27%<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">9.01%<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">10.68%<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">17.04%<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">September 2026<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">Nuvama<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">53.98%<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">19.00%<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">8.49%<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">18.53%<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">June 2026<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2><span class=\"ez-toc-section\" id=\"Risks_to_Weigh_in_Debt_to_Equity_Above_1_Stocks\"><\/span><strong>Risks to Weigh in Debt to Equity Above 1 Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Being careful with debt to equity above 1 stocks means looking at what can slow the story as well as what can speed it up. Four points matter most:<\/p>\n<ul>\n<li>Past growth may not repeat.<\/li>\n<li>Share prices can move sharply in either direction.<\/li>\n<li><strong>Valuation:<\/strong> Sundaram Finance trades at a PE of 20.17 against an industry PE of 17.70, so earnings need to keep growing to support the price.<\/li>\n<li><strong>Concentration:<\/strong> Holding all 4 names puts the allocation in one sector, so size each position to match your risk appetite.<\/li>\n<\/ul>\n<h2><span class=\"ez-toc-section\" id=\"How_to_Choose_Between_Debt_to_Equity_Above_1_Stocks\"><\/span><strong>How to Choose Between Debt to Equity Above 1 Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Picking from debt to equity above 1 stocks comes down to four checks, applied in order.<\/p>\n<ol>\n<li>Check balance sheet strength first, and prefer a debt-to-equity ratio below 1 for non-financial companies.<\/li>\n<li>Compare each PE with the industry PE (17.70 to 60.75) and ask whether the growth rate justifies any gap.<\/li>\n<li>Track net profit growth, the operating margin and the return on equity in every quarterly result.<\/li>\n<li>Stagger entries across quarters and review institutional holding every reporting season.<\/li>\n<\/ol>\n<p style=\"margin-top:24px;\"><em>Download the <a href=\"http:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a> or <a href=\"http:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&#038;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a> to track Ashok Leyland, Sundaram Finance, Narayana Health and Nuvama live prices.<\/em><\/p>\n<h2><span class=\"ez-toc-section\" id=\"Conclusion\"><\/span><strong>Conclusion<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Among debt to equity above 1 stocks, Ashok Leyland stands out for the largest market cap at Rs 86,231 crore, Sundaram Finance for the strongest latest-quarter profit growth at 38.14%, Narayana Health for the fastest profit growth, 24.06% a year since FY22 and Nuvama for the highest return on equity at 25.26%. Which one suits a portfolio depends on how much valuation risk it can carry, so staggering entries and reviewing each quarterly result is a sound habit. Investors comparing debt to equity above 1 stocks should rank them on growth, financial strength and the price paid, and anyone who wants personalised guidance can consult a SEBI-registered advisor before acting.<\/p>\n<div style=\"background:#CC0000;border-radius:8px;padding:16px 20px;margin:24px 0;\">\n<p style=\"color:#FFFFFF;font-size:13px;line-height:1.7;margin:0;\"><strong style=\"color:#FFFFFF;\">Disclaimer:<\/strong> Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).<\/p>\n<\/p><\/div>\n<h2><span class=\"ez-toc-section\" id=\"Frequently_Asked_Questions_on_Debt_to_Equity_Above_1_Stocks_to_Watch\"><\/span><strong>Frequently Asked Questions on Debt to Equity Above 1 Stocks to Watch<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"Which_are_the_best_debt_to_equity_above_1_stocks_to_watch_for_multibagger_potential\"><\/span><strong>Which are the best debt to equity above 1 stocks to watch for multibagger potential?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Ashok Leyland, Sundaram Finance, Narayana Health and Nuvama are the 4 names this list highlights, with market caps of Rs 86,231 crore, Rs 44,764 crore, Rs 34,864 crore and Rs 32,827 crore respectively. Ashok Leyland is notable for the largest market cap at Rs 86,231 crore. Sundaram Finance stands out for the strongest latest-quarter profit growth at 38.14%. Narayana Health offers the fastest profit growth, 24.06% a year since FY22. Nuvama brings the highest return on equity at 25.26%. These are watchlist names for debt to equity above 1 stocks, not recommendations, so match each one to your own risk profile and time horizon.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Is_Nuvama_a_good_stock_for_long-term_investors\"><\/span><strong>Is Nuvama a good stock for long-term investors?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Nuvama has a return on equity of 25.26%, a PE of 30.34 against an industry PE of 33.31 and a market cap of Rs 32,827 crore. FY26 revenue rose 11.52%, and June 2026 quarter net profit grew 15.83%. Long-term returns in debt to equity above 1 stocks depend on earnings growth and the price paid at entry, so staggering purchases and consulting a SEBI-registered advisor is sensible.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Can_Narayana_Health_become_a_multibagger_from_here\"><\/span><strong>Can Narayana Health become a multibagger from here?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Narayana Health has already gained 225.59% in five years, so another multi-fold move would need sustained earnings growth. A multibagger outcome in debt to equity above 1 stocks requires earnings to keep growing faster than the market for several years. Net profit has compounded at 24.06% a year since FY22, and FY26 revenue rose 43.43%. At a PE of 42.69 against an industry PE of 60.75, valuation should be checked against that growth before investing.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_market_cap_of_Ashok_Leyland_Sundaram_Finance_Narayana_Health_and_Nuvama\"><\/span><strong>What is the market cap of Ashok Leyland, Sundaram Finance, Narayana Health and Nuvama?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> As of 28 October 2026, Ashok Leyland has a market cap of Rs 86,231 crore, Sundaram Finance has a market cap of Rs 44,764 crore, Narayana Health has a market cap of Rs 34,864 crore and Nuvama has a market cap of Rs 32,827 crore. All of them qualify as midcaps. Market cap changes daily with the share price, so check the latest figure on the Univest Screener or on NSE before taking a decision on debt to equity above 1 stocks.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_are_the_risks_of_investing_in_debt_to_equity_above_1_stocks\"><\/span><strong>What are the risks of investing in debt to equity above 1 stocks?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The main risks are market swings, slower growth than expected and valuations that already reflect good news. Companies with strong balance sheets and steady earnings handle these better. Sundaram Finance trades at a PE of 20.17 against an industry PE of 17.70, so earnings growth needs to hold up.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Is_Sundaram_Finance_trading_below_its_industry_PE\"><\/span><strong>Is Sundaram Finance trading below its industry PE?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Sundaram Finance trades at a PE of 20.17 against an industry PE of 17.70. A lower PE means investors pay less for each rupee of earnings, but it should be read with growth (net profit has compounded at 17.10% a year since FY22 and FY26 revenue rose 15.30%) and balance sheet strength before drawing a conclusion.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"How_much_do_institutions_hold_in_Ashok_Leyland_Sundaram_Finance_Narayana_Health_and_Nuvama\"><\/span><strong>How much do institutions hold in Ashok Leyland, Sundaram Finance, Narayana Health and Nuvama?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> As of the latest reported quarter, FII and DII together hold 36.44% of Ashok Leyland (20.68% and 15.76%), 26.58% of Sundaram Finance (18.58% and 8.00%), 19.69% of Narayana Health (9.01% and 10.68%) and 27.49% of Nuvama (19.00% and 8.49%). Rising institutional holding is a useful signal in debt to equity above 1 stocks, though it should be read with earnings trends rather than on its own.<\/p>\n<p><script type=\"application\/ld+json\">{\"@context\":\"https:\/\/schema.org\",\"@type\":\"FAQPage\",\"mainEntity\":[{\"@type\":\"Question\",\"name\":\"Which are the best debt to equity above 1 stocks to watch for multibagger potential?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Ashok Leyland, Sundaram Finance, Narayana Health and Nuvama are the 4 names this list highlights, with market caps of Rs 86,231 crore, Rs 44,764 crore, Rs 34,864 crore and Rs 32,827 crore respectively. Ashok Leyland is notable for the largest market cap at Rs 86,231 crore. Sundaram Finance stands out for the strongest latest-quarter profit growth at 38.14%. Narayana Health offers the fastest profit growth, 24.06% a year since FY22. Nuvama brings the highest return on equity at 25.26%. These are watchlist names for debt to equity above 1 stocks, not recommendations, so match each one to your own risk profile and time horizon.\"}},{\"@type\":\"Question\",\"name\":\"Is Nuvama a good stock for long-term investors?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Nuvama has a return on equity of 25.26%, a PE of 30.34 against an industry PE of 33.31 and a market cap of Rs 32,827 crore. FY26 revenue rose 11.52%, and June 2026 quarter net profit grew 15.83%. Long-term returns in debt to equity above 1 stocks depend on earnings growth and the price paid at entry, so staggering purchases and consulting a SEBI-registered advisor is sensible.\"}},{\"@type\":\"Question\",\"name\":\"Can Narayana Health become a multibagger from here?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Narayana Health has already gained 225.59% in five years, so another multi-fold move would need sustained earnings growth. A multibagger outcome in debt to equity above 1 stocks requires earnings to keep growing faster than the market for several years. Net profit has compounded at 24.06% a year since FY22, and FY26 revenue rose 43.43%. At a PE of 42.69 against an industry PE of 60.75, valuation should be checked against that growth before investing.\"}},{\"@type\":\"Question\",\"name\":\"What is the market cap of Ashok Leyland, Sundaram Finance, Narayana Health and Nuvama?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"As of 28 October 2026, Ashok Leyland has a market cap of Rs 86,231 crore, Sundaram Finance has a market cap of Rs 44,764 crore, Narayana Health has a market cap of Rs 34,864 crore and Nuvama has a market cap of Rs 32,827 crore. All of them qualify as midcaps. Market cap changes daily with the share price, so check the latest figure on the Univest Screener or on NSE before taking a decision on debt to equity above 1 stocks.\"}},{\"@type\":\"Question\",\"name\":\"What are the risks of investing in debt to equity above 1 stocks?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"The main risks are market swings, slower growth than expected and valuations that already reflect good news. Companies with strong balance sheets and steady earnings handle these better. Sundaram Finance trades at a PE of 20.17 against an industry PE of 17.70, so earnings growth needs to hold up.\"}},{\"@type\":\"Question\",\"name\":\"Is Sundaram Finance trading below its industry PE?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Sundaram Finance trades at a PE of 20.17 against an industry PE of 17.70. A lower PE means investors pay less for each rupee of earnings, but it should be read with growth (net profit has compounded at 17.10% a year since FY22 and FY26 revenue rose 15.30%) and balance sheet strength before drawing a conclusion.\"}},{\"@type\":\"Question\",\"name\":\"How much do institutions hold in Ashok Leyland, Sundaram Finance, Narayana Health and Nuvama?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"As of the latest reported quarter, FII and DII together hold 36.44% of Ashok Leyland (20.68% and 15.76%), 26.58% of Sundaram Finance (18.58% and 8.00%), 19.69% of Narayana Health (9.01% and 10.68%) and 27.49% of Nuvama (19.00% and 8.49%). Rising institutional holding is a useful signal in debt to equity above 1 stocks, though it should be read with earnings trends rather than on its own.\"}}]}<\/script><\/p>\n","protected":false},"excerpt":{"rendered":"<p>4 midcap debt to equity above 1 stocks compared on market cap, PE, ROE, growth and institutional holding: Ashok Leyland, Sundaram Finance, Narayana Health and Nuvama.<\/p>\n","protected":false},"author":33,"featured_media":331601,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[845],"tags":[17714,17713],"class_list":["post-331602","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-best-stocks","tag-debt-to-equity-above-1-sector","tag-debt-to-equity-above-1-stocks"],"metadata":{"rank_math_internal_links_processed":["1"],"_thumbnail_id":["331601"],"rank_math_title":["Debt to Equity Above 1 Stocks to Watch in 2026"],"rank_math_description":["Debt to equity above 1 stocks to watch for multibagger potential: Ashok Leyland, Sundaram Finance, Narayana Health and Nuvama. Compare market cap, PE, ROE and growth."],"rank_math_focus_keyword":["debt to equity above 1 stocks"],"rank_math_robots":["a:2:{i:0;s:7:\"noindex\";i:1;s:8:\"nofollow\";}"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/10\/4-midcap-debt-to-equity-above-1-stocks-to-watch-for-future-multibagger-potential.webp","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/331602","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/33"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=331602"}],"version-history":[{"count":1,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/331602\/revisions"}],"predecessor-version":[{"id":331603,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/331602\/revisions\/331603"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/331601"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=331602"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=331602"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=331602"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}